First cohort dosed in Phase 1 clinical study of sustained release treprostinil injection for treatment of PAH
Lund — 21 December 2017 — Camurus (Nasdaq Stockholm; CAMX) today announced the dosing of the first cohort in an open-label, dose-escalating Phase 1 study assessing safety, tolerability, and pharmacokinetics of single and repeated doses of CAM2043 (treprostinil FluidCrystal® Injection Depot) in healthy volunteers. CAM2043 is an investigational subcutaneous treprostinil depot under development for the treatment of pulmonary arterial hypertension (PAH). Continuous infusion of treprostinil is a known efficacious treatment for PAH, but it is also associated with complications for the patients.